MA30428B1 - Derives de dihydropyrazolopyrimidinones - Google Patents
Derives de dihydropyrazolopyrimidinonesInfo
- Publication number
- MA30428B1 MA30428B1 MA31411A MA31411A MA30428B1 MA 30428 B1 MA30428 B1 MA 30428B1 MA 31411 A MA31411 A MA 31411A MA 31411 A MA31411 A MA 31411A MA 30428 B1 MA30428 B1 MA 30428B1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- formula
- compounds represented
- alkyl group
- dihydropyrazolopyrimidinones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'INVENTION A TRAIT À DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE : A1 EST SÉLECTIONNÉ PARMI LES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (AA1); R1 REPRÉSENTE UN GROUPE ALCÉNYLE INFÉRIEUR OU UN GROUPE ALCYNYLE INFÉRIEUR; R2 REPRÉSENTE UN GROUPE PHÉNYLE, PYRIDYLE OU THIÉNYLE; R5 ET R6 REPRÉSENTENT UN ATOME D'HYDROGÈNE, UN GROUPE ALKYLE INFÉRIEUR OU UN GROUPE HYDROXY ALKYLE INFÉRIEUR, ETC. LES COMPOSÉS SELON L'INVENTION PRÉSENTENT UN EFFET INHIBITEUR DE LA KINASE WEE1 ET SONT DONC UTILES DANS LE DOMAINE MÉDICAL, NOTAMMENT POUR LE TRAITEMENT DE DIVERS CANCERS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006124208 | 2006-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30428B1 true MA30428B1 (fr) | 2009-05-04 |
Family
ID=38655640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31411A MA30428B1 (fr) | 2006-04-27 | 2008-11-24 | Derives de dihydropyrazolopyrimidinones |
Country Status (39)
Country | Link |
---|---|
US (4) | US7834019B2 (fr) |
EP (2) | EP2017278B1 (fr) |
JP (2) | JP4513919B2 (fr) |
KR (1) | KR101409161B1 (fr) |
CN (1) | CN101432284B (fr) |
AR (1) | AR060635A1 (fr) |
AT (1) | ATE475662T1 (fr) |
AU (1) | AU2007244185B2 (fr) |
BR (1) | BRPI0710081A2 (fr) |
CA (1) | CA2650119C (fr) |
CR (1) | CR10359A (fr) |
CY (2) | CY1111069T1 (fr) |
DE (1) | DE602007008085D1 (fr) |
DK (2) | DK2016080T3 (fr) |
DO (1) | DOP2007000084A (fr) |
EC (1) | ECSP088812A (fr) |
ES (2) | ES2609087T3 (fr) |
GT (1) | GT200800211A (fr) |
HK (1) | HK1132498A1 (fr) |
HN (1) | HN2008001532A (fr) |
HR (2) | HRP20100563T1 (fr) |
HU (1) | HUE032987T2 (fr) |
IL (1) | IL194367A (fr) |
LT (1) | LT2017278T (fr) |
MA (1) | MA30428B1 (fr) |
MX (1) | MX2008013063A (fr) |
MY (1) | MY145408A (fr) |
NO (1) | NO341617B1 (fr) |
NZ (1) | NZ571196A (fr) |
PE (1) | PE20080695A1 (fr) |
PL (2) | PL2017278T3 (fr) |
PT (2) | PT2016080E (fr) |
RU (1) | RU2437885C2 (fr) |
SI (2) | SI2017278T1 (fr) |
SV (1) | SV2009003060A (fr) |
TW (1) | TWI409262B (fr) |
UA (1) | UA96152C2 (fr) |
WO (2) | WO2007126122A1 (fr) |
ZA (1) | ZA200807748B (fr) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
US8198281B2 (en) | 2007-04-25 | 2012-06-12 | Merck Sharp & Dohme Corp. | Crystalline forms of dihydropyrazolopyrimidinone |
WO2008141385A1 (fr) * | 2007-05-21 | 2008-11-27 | Biota Scientific Management Pty Ltd | Inhibiteurs de polymérases virales |
JPWO2009054332A1 (ja) * | 2007-10-23 | 2011-03-03 | 萬有製薬株式会社 | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
ES2430053T3 (es) * | 2008-06-12 | 2013-11-18 | Merck Sharp & Dohme Corp. | Procedimiento para producir derivados de bicicloanilina |
AU2009325400A1 (en) * | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
WO2010076887A1 (fr) * | 2009-01-05 | 2010-07-08 | Banyu Pharmaceutical Co.,Ltd. | Biomarqueurs prédictifs utiles pour une thérapie anticancéreuse à médiation par un inhibiteur de wee1 |
EP2401281A4 (fr) * | 2009-02-25 | 2012-08-15 | Msd Kk | Dérivé de pyrimido-pyrimido-indazole |
US20120157342A1 (en) * | 2009-09-02 | 2012-06-21 | Shinji Mizuarai | Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor |
SI2477628T1 (sl) | 2009-09-15 | 2014-11-28 | Merck Sharp & Dohme Corp. | Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona |
RU2017127088A (ru) | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
WO2012147904A1 (fr) * | 2011-04-27 | 2012-11-01 | 日本ゼオン株式会社 | Composé polymérisable, composition polymérisable, polymère et matière optiquement anisotrope |
US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
EP2755482B1 (fr) | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combinaison de mk-1775 et mk-8776 pour le traitement du cancer |
JP2014530867A (ja) | 2011-10-20 | 2014-11-20 | アッヴィ・インコーポレイテッド | キナーゼのピリドピリミジノン阻害剤 |
MX2014010176A (es) * | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
WO2014062454A1 (fr) * | 2012-10-15 | 2014-04-24 | Merck Sharp & Dohme Corp. | Compositions et procédés de traitement du cancer |
CA2892361A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Utilisation d'un inhibiteur wee1 pour traiter un cancer caracterise par de faibles niveaux d'expression de proteines tyrosine et threonine kinases 1 (pkmyt1) associee a la membrane |
CA2909160C (fr) | 2013-04-09 | 2021-05-25 | Lixte Biotechnology, Inc. | Formulations d'oxabicycloheptanes et d'oxabicycloheptenes |
GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
KR20170045751A (ko) * | 2014-12-17 | 2017-04-27 | 데루타-후라이 화마 가부시키가이샤 | 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물 |
WO2016168638A1 (fr) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones utilisées en tant que modulateurs de la signalisation du tnf |
WO2016168633A1 (fr) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones utilisées en tant que modulateurs de la signalisation du tnf |
US9856253B2 (en) | 2015-04-17 | 2018-01-02 | Abbvie, Inc. | Tricyclic modulators of TNF signaling |
MY191938A (en) * | 2015-09-01 | 2022-07-19 | Taiho Pharmaceutical Co Ltd | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof |
CN105130986B (zh) * | 2015-09-30 | 2017-07-18 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
CA3003737C (fr) * | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Inhibiteurs de la kinase wee1 et leurs procedes de fabrication et d'uti lisation |
CN106271589B (zh) * | 2016-06-23 | 2018-12-28 | 中山市美捷时包装制品有限公司 | 一种用于预装阀杆、弹簧、垫片的组装设备 |
GB201612092D0 (en) * | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
ES2816003T3 (es) | 2016-09-15 | 2021-03-31 | Boehringer Ingelheim Int | Compuestos de heteroaril carboxamida como inhibidores de RIPK2 |
CN106719769A (zh) * | 2016-11-28 | 2017-05-31 | 山东农业大学 | 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物 |
CN110198943B (zh) * | 2017-01-23 | 2021-04-16 | 石家庄智康弘仁新药开发有限公司 | 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 |
GB201703881D0 (en) * | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
WO2018171633A1 (fr) * | 2017-03-23 | 2018-09-27 | 上海迪诺医药科技有限公司 | Dérivé macrocyclique de pyrazol[3,4-d]pyrimidin-3-one, composition pharmaceutique et utilisation associée |
SG11201908788YA (en) | 2017-03-31 | 2019-10-30 | Seattle Genetics Inc | Combinations of chk1- and wee1 - inhibitors |
RU2020105058A (ru) * | 2017-08-01 | 2021-09-02 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она |
WO2019037678A1 (fr) * | 2017-08-24 | 2019-02-28 | 上海迪诺医药科技有限公司 | Dérivé de pyrazolo[3,4-d]pyrimidin-3-one, composition pharmaceutique et utilisation associée |
WO2019074979A1 (fr) * | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | Composés hétérocycliques et leurs utilisations |
US10807994B2 (en) | 2017-10-09 | 2020-10-20 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
BR112020008664A8 (pt) | 2017-11-01 | 2023-01-17 | Shijiazhuang Sagacity New Drug Dev Co Ltd | Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo |
WO2019096322A1 (fr) * | 2017-11-20 | 2019-05-23 | 上海医药集团股份有限公司 | Composé de pyrazolone-pyrimidine, son procédé de préparation et son application |
WO2019134539A1 (fr) * | 2018-01-05 | 2019-07-11 | 四川科伦博泰生物医药股份有限公司 | Composé de dihydropyrazolone et de pyrimidine, son procédé de préparation et son utilisation |
WO2019165204A1 (fr) | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | Composés de 1,2-dihydro-3 h-pyrazolo [3,4-d] pyrimidine-3-one utilisés en tant qu'inhibiteurs de la kinase we -1 |
US20200405723A1 (en) * | 2018-02-28 | 2020-12-31 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
MX2020009372A (es) * | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. |
CN108653282B (zh) * | 2018-06-28 | 2020-08-14 | 中国科学院昆明植物研究所 | 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用 |
US20210403451A1 (en) | 2018-10-26 | 2021-12-30 | Wenyuan Qian | Pyrimidopyrazolone derivative as wee1 inhibitor and use thereof |
CN113480541B (zh) * | 2019-03-07 | 2022-09-02 | 湖南化工研究院有限公司 | 咪唑并吡啶化合物及其中间体的制备方法 |
EP3943496A4 (fr) * | 2019-03-22 | 2022-05-18 | Shouyao Holdings (Beijing) Co., Ltd. | Inhibiteur de wee1 ainsi que sa préparation et son utilisation |
KR20210150476A (ko) | 2019-04-09 | 2021-12-10 | 누베이션 바이오 인크. | 헤테로시클릭 화합물 및 그의 용도 |
WO2020210320A1 (fr) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées |
CA3138240A1 (fr) | 2019-04-30 | 2020-11-05 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | Formes cristallines d'un compose inhibiteur de wee1 et utilisation connexe |
CN112142748B (zh) | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
WO2020259703A1 (fr) * | 2019-06-28 | 2020-12-30 | 上海医药集团股份有限公司 | Composé de pyrazolopyrimidine, son procédé de préparation et ses applications |
AU2020369996A1 (en) | 2019-10-25 | 2022-06-02 | Astrazeneca Ab | Methods of treating cancer |
CN113387962A (zh) * | 2020-03-12 | 2021-09-14 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
US20230159540A1 (en) | 2020-06-17 | 2023-05-25 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR |
KR102549484B1 (ko) * | 2020-12-08 | 2023-06-29 | 한국화학연구원 | 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2022171128A1 (fr) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | Dérivé de pyrazolo[3,4-d]pyrimidine-3-cétone servant d'inhibiteur de wee-1 |
CN116848117A (zh) * | 2021-02-09 | 2023-10-03 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的稠环化合物 |
CN116867787A (zh) * | 2021-02-09 | 2023-10-10 | 微境生物医药科技(上海)有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物 |
CN115197221B (zh) * | 2021-04-02 | 2024-05-24 | 轩竹(北京)医药科技有限公司 | 二氢吡唑并嘧啶酮类大环衍生物及其用途 |
KR20240004584A (ko) | 2021-04-29 | 2024-01-11 | 노파르티스 아게 | 탈유비퀴티나아제-표적화 키메라 및 관련된 방법 |
BR112023022236A2 (pt) | 2021-04-30 | 2024-02-06 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto de fórmula geral (1) ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato; composição farmacêutica; e; uso do composto ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato |
CN115403582A (zh) | 2021-05-28 | 2022-11-29 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其用途 |
WO2023041066A1 (fr) * | 2021-09-18 | 2023-03-23 | 优领医药科技(香港)有限公司 | Dérivé de dihydropyrazolone contenant de la pyrimidine, sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation et son application |
CN113880844B (zh) * | 2021-09-29 | 2023-02-14 | 武汉九州钰民医药科技有限公司 | Wee1蛋白激酶抑制剂adavosertib的化学合成方法 |
CN113735863A (zh) * | 2021-09-29 | 2021-12-03 | 武汉九州钰民医药科技有限公司 | Wee1抑制剂adavosertib的制备工艺 |
WO2023072301A1 (fr) * | 2021-11-01 | 2023-05-04 | 正大天晴药业集团股份有限公司 | Composé pyrazolo[3,4-d]pyrimidin-3-one et son utilisation médicale |
CN116462687A (zh) * | 2022-01-18 | 2023-07-21 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
CN116836184A (zh) * | 2022-03-25 | 2023-10-03 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
CN115073460B (zh) * | 2022-07-13 | 2023-07-25 | 苏州施安鼎泰生物医药技术有限公司 | 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用 |
WO2024012549A1 (fr) * | 2022-07-15 | 2024-01-18 | 映恩生物制药(苏州)有限公司 | Composé hétérocyclique à cinq chaînons pyrimido, son procédé de préparation et son utilisation |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA07174A (fr) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent. |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP2628707B2 (ja) * | 1987-08-26 | 1997-07-09 | 三井製薬工業株式会社 | ピリミジン類及びその薬学的に許容される塩類 |
US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
SK283693B6 (sk) | 1990-09-28 | 2003-12-02 | Smithkline Beecham Corporation | Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli |
US5191082A (en) | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
US5200524A (en) | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
US5162532A (en) | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
US5243050A (en) | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
US5247089A (en) | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
JP3025602B2 (ja) | 1993-05-21 | 2000-03-27 | デビオファーム エス.アー. | 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法 |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
CA2222231A1 (fr) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Anticorps et fragments d'anticorps inhibant la croissance des tumeurs |
JP3154399B2 (ja) | 1996-07-04 | 2001-04-09 | デビオファーム エス.アー. | 白金化合物の製造方法 |
CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
SE0103649D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
BR0309783A (pt) | 2002-04-26 | 2005-03-22 | Warner Lambert Co | Inibidores de quinases de pontos de controlo (wee1 e chk1) |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2004065378A1 (fr) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire |
WO2004072063A1 (fr) * | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrroles a substitution heteroaryle servant d'inhibiteurs de proteines kinases |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
US20050250836A1 (en) * | 2004-05-03 | 2005-11-10 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
DK2433943T3 (da) | 2004-07-01 | 2013-12-16 | Daiichi Sankyo Co Ltd | Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet |
ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
WO2006091737A1 (fr) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulateurs de l'activite de gsk-3 |
PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
-
2007
- 2007-04-24 PE PE2007000511A patent/PE20080695A1/es active IP Right Grant
- 2007-04-24 AR ARP070101763A patent/AR060635A1/es active IP Right Grant
- 2007-04-25 DE DE602007008085T patent/DE602007008085D1/de active Active
- 2007-04-25 KR KR1020087026239A patent/KR101409161B1/ko active IP Right Grant
- 2007-04-25 PL PL07742851T patent/PL2017278T3/pl unknown
- 2007-04-25 PT PT07742843T patent/PT2016080E/pt unknown
- 2007-04-25 MX MX2008013063A patent/MX2008013063A/es active IP Right Grant
- 2007-04-25 WO PCT/JP2007/059408 patent/WO2007126122A1/fr active Application Filing
- 2007-04-25 DK DK07742843.1T patent/DK2016080T3/da active
- 2007-04-25 RU RU2008146759/04A patent/RU2437885C2/ru active
- 2007-04-25 PL PL07742843T patent/PL2016080T3/pl unknown
- 2007-04-25 JP JP2008513330A patent/JP4513919B2/ja active Active
- 2007-04-25 SI SI200731875A patent/SI2017278T1/sl unknown
- 2007-04-25 ES ES07742851.4T patent/ES2609087T3/es active Active
- 2007-04-25 AU AU2007244185A patent/AU2007244185B2/en active Active
- 2007-04-25 ES ES07742843T patent/ES2348751T3/es active Active
- 2007-04-25 LT LTEP07742851.4T patent/LT2017278T/lt unknown
- 2007-04-25 NZ NZ571196A patent/NZ571196A/en unknown
- 2007-04-25 CA CA2650119A patent/CA2650119C/fr active Active
- 2007-04-25 SI SI200730373T patent/SI2016080T1/sl unknown
- 2007-04-25 CN CN2007800150647A patent/CN101432284B/zh active Active
- 2007-04-25 DK DK07742851.4T patent/DK2017278T3/en active
- 2007-04-25 HU HUE07742851A patent/HUE032987T2/en unknown
- 2007-04-25 US US11/789,548 patent/US7834019B2/en active Active
- 2007-04-25 AT AT07742843T patent/ATE475662T1/de active
- 2007-04-25 WO PCT/JP2007/059416 patent/WO2007126128A1/fr active Application Filing
- 2007-04-25 US US12/226,707 patent/US7935708B2/en active Active
- 2007-04-25 EP EP07742851.4A patent/EP2017278B1/fr active Active
- 2007-04-25 PT PT77428514T patent/PT2017278T/pt unknown
- 2007-04-25 UA UAA200813667A patent/UA96152C2/ru unknown
- 2007-04-25 EP EP07742843A patent/EP2016080B1/fr active Active
- 2007-04-25 BR BRPI0710081-7A patent/BRPI0710081A2/pt not_active Application Discontinuation
- 2007-04-27 TW TW096114902A patent/TWI409262B/zh active
- 2007-04-27 DO DO2007000084A patent/DOP2007000084A/es unknown
-
2008
- 2008-09-09 ZA ZA200807748A patent/ZA200807748B/xx unknown
- 2008-09-18 MY MYPI20083651A patent/MY145408A/en unknown
- 2008-09-25 IL IL194367A patent/IL194367A/en active IP Right Grant
- 2008-10-09 EC EC2008008812A patent/ECSP088812A/es unknown
- 2008-10-10 GT GT200800211A patent/GT200800211A/es unknown
- 2008-10-10 SV SV2008003060A patent/SV2009003060A/es unknown
- 2008-10-10 CR CR10359A patent/CR10359A/es unknown
- 2008-10-10 HN HN2008001532A patent/HN2008001532A/es unknown
- 2008-11-24 MA MA31411A patent/MA30428B1/fr unknown
- 2008-11-26 NO NO20084968A patent/NO341617B1/no unknown
-
2009
- 2009-10-29 HK HK09110110.5A patent/HK1132498A1/xx unknown
-
2010
- 2010-02-08 JP JP2010025458A patent/JP5167291B2/ja active Active
- 2010-10-18 HR HR20100563T patent/HRP20100563T1/hr unknown
- 2010-10-27 CY CY20101100973T patent/CY1111069T1/el unknown
-
2011
- 2011-03-22 US US13/053,798 patent/US8791125B2/en active Active
-
2014
- 2014-06-24 US US14/312,982 patent/US20140303178A1/en not_active Abandoned
-
2016
- 2016-12-21 HR HRP20161763TT patent/HRP20161763T1/hr unknown
-
2017
- 2017-01-27 CY CY20171100129T patent/CY1118526T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30428B1 (fr) | Derives de dihydropyrazolopyrimidinones | |
MA31319B1 (fr) | Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
MA31419B1 (fr) | Derives de pyridine | |
MA30526B1 (fr) | Inhibiteurs de prolyle hydroxylase | |
MA29926B1 (fr) | Derives de pyrazine | |
MA28747B1 (fr) | Dérivés de pyridine | |
TW200519088A (en) | Aryl or heteroaryl amide compounds | |
TN2009000033A1 (fr) | Derives de pyrazole servant d'inhibiteurs du cytochrome p450 | |
TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
MA31894B1 (fr) | Composes organiques | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
TNSN06370A1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
MA30075B1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
SG132672A1 (en) | 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
MA32965B1 (fr) | Derives de sulfonamides | |
TN2010000248A1 (fr) | Derives d'indolinone et procede pour leur fabrication | |
ATE393146T1 (de) | 3,6-substituierte 5-arylamino-1h-pyidin-2-on derivative und verwandte verbindungen als poly(adp-ribose)polymerase (parp) inhibitoren zur behandlung von durch nekose oder apoptose verursachten gewebeschäden oder erkankungen | |
TNSN08139A1 (fr) | Composes therapeutiques | |
MA30228B1 (fr) | Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4 | |
TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues |